Revisit Every OncLive On Air Episode From March 2026

In case you missed any, below is a recap of the episodes of OncLive On Air® that aired in March 2026. Check out our podcast page for a full episode lineup and to stay up to date with all the latest releases!

How an Interest in Scientific Intricacies Evolved to Transform the Biotechnology Field: With D. Ross Camidge, MD, PhD; and Tim Clackson, PhD

In this episode of How This Is Building Me, host D. Ross Camidge, MD, PhD, was joined by Tim Clackson, PhD, of IDRx, who talked about his career in biotechnology, which included the development of ponatinib (Iclusig) for the treatment of patients with chronic myeloid leukemia, as well as evolving leadership roles and entrepreneurship ventures.

Incorporating TROP2-Targeted ADCs Into Lung Cancer Treatment Algorithms: With Eric K. Singhi, MD

In this episode of OncLive On Air, we sat down with Eric K. Singhi, MD, of The University of Texas MD Anderson Cancer Center in Houston, who explained the evolution of TROP2-directed antibody-drug conjugates (ADCs) for disease management across lung cancer subtypes.

FDA Approval Insights: SC Daratumumab Plus VRd Provides Additional Treatment Avenue in Transplant-Ineligible, Newly Diagnosed Myeloma: With Saad Z. Usmani, MD, MBA, FACP, FASCO

In this episode, Saad Z. Usmani, MD, MBA, FACP, FASCO, of Memorial Sloan Kettering Cancer Center in New York, New York, highlighted the significance of the FDA approval of daratumumab and hyaluronidase-fihj (Darzalex Faspro) plus bortezomib (Velcade), lenalidomide (Revlimid), and dexamethasone for the treatment of adult patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant.

Leading Breast Oncologists Share Advice and Optimism for Future Women in Oncology: With Kelly E. McCann, MD, PhD, and Sara Nunnery, MD, MSCI

In this episode, Kelly E. McCann, MD, PhD, of the University of California system, and Sara Nunnery, MD, MSCI, of Tennessee Oncology in Nashville, discussed their perspectives and experiences about boundary setting, work-life harmony, advocating for career opportunities, and more in honor of International Women’s Day.

Exploring CAR T in Solid Tumors, Clinical Trials, and Cancer Incidence Questions

In this episode, Sonali Smith, MD, of UChicago Medicine in Illinois, spotlighted emerging CAR T-cell therapies in solid tumor management, the importance of conducting clinical trials in hematologic oncology, and rising cancer incidence rates among young adults.

Trans-Arterial Micro-Perfusion Could Boost Systemic Chemotherapy Efficacy in Unresectable Pancreatic Cancer: With Gregory J. Tiesi, MD, FACS, FSSO; Anthony Scholer, MD, FACS, FSSO; and Eric Pletcher, MD

In this episode, host Gregory J. Tiesi, MD, FACS, FSSO, of the Hackensack Meridian Jersey Shore University Medical Center in Neptune, New Jersey, was joined by Hackensack Meridian colleagues Anthony Scholer, MD, FACS, FSSO, and Eric Pletcher, MD, to discuss the evolving use of trans-arterial micro-perfusion in patients with locally advanced pancreatic ductal adenocarcinoma.

How a Devotion to Heath Care Conquered Societal Barriers: With D. Ross Camidge, MD, PhD; and Khari Reed, MHSA, FACHE

In this episode of How This Is Building Me, Dr Camidge and Khari Reed, MHSA, FACHE, of HonorHealth in Scottsdale, Arizona, discussed Dr Reed’s versatile health care career, which has included leading an oncology service line through the COVID-19 pandemic, volunteer work, establishing an incident command center, and prioritizing high-quality oncology care.

Novel Treatment Combinations for B-ALL May Help Patients Safely Achieve Remission: With Colin Vale, MD

In this episode, Colin Vale, MD, of the Emory University School of Medicine in Atlanta, Georgia, spotlighted clinical findings with blinatumomab (Blincyto) in combination with ponatinib in patients with Philadelphia chromosome–positive B-cell acute lymphoblastic leukemia (ALL).

ctDNA Testing at Progression May Help Detect Resistance and Guide Sequencing in GIST: With Drs Jonathan Trent, MD, PhD, and Neeta Somaiah, MD

In this episode, Jonathan Trent, MD, PhD, of the University of Miami Miller School of Medicine, in Florida, and Neeta Somaiah, MD, of The University of Texas MD Anderson Cancer Center, talked through the use of circulating tumor DNA (ctDNA) testing in gastrointestinal stromal tumors, the importance of parsing drivers of both initial disease and secondary resistance, and how ctDNA test results factor into treatment decision-making and sequencing.

Watch the video podcast for more insights!

ASH Guidelines Provide Key Recommendations for AYA Acute Lymphoblastic Leukemia Management: With Wendy Stock, MD

In this episode, Wendy Stock, MD, of the University of Chicago Medicine Comprehensive Cancer Center, talked through highlights from the ASH 2026 Guidelines for Frontline Management of Acute Lymphoblastic Leukemia (ALL) in Adolescents and Young Adults.

ASCO GU 2026 Takeaways

In this episode of Two Onc Docs, hosts Samantha A. Armstrong, MD, of Indiana University Health in Indianapolis, and Karine Tawagi, MD, of the University of Illinois in Chicago, spotlighted practice-informing data presented at the 2026 Genitourinary Cancers Symposium (ASCO GU) across prostate, bladder, kidney, and testicular cancer.

Real-World Data Support ctDNA-Guided Treatment Strategies in FGFR2-Altered Cholangiocarcinoma: With Marina Baretti, MD

In this episode, Marina Baretti, MD, of the Sidney Kimmel Comprehensive Cancer Center in Baltimore, Maryland, noted considerations for the real-world use of ctDNA monitoring in patients with cholangiocarcinoma.

Real-World Analyses Help Make Sense of Multiple Approved CAR T-Cell Therapies for ALL: With Jae Park, MD

In this episode, Jae Park, MD, of Memorial Sloan Kettering Cancer Center, gave a comprehensive overview of the status of CAR T-cell therapy in ALL management, including considerations for integrating this treatment modality into clinical practice and how to choose between the FDA-approved treatments.

T-DXd Trials Transform Treatment for HER2-Positive Breast Cancer: With Sara Nunnery, MD, MSCI; and Kelly E. McCann, MD, PhD

In the inaugural episode of Breast Cancer Briefing, Dr Nunnery was rejoined by Dr McCann to chat about all things HER2-positive breast cancer, from evolving prognoses to breakthroughs with targeted therapies, ADCs, and more.

Watch the video podcast for more commentary!

New Trials and Targeted Approaches Advance the Precision of GI Cancer Care: With John Marshall, MD; and Christopher Lieu, MD

In this episode, John Marshall, MD, of the Georgetown Lombardi Comprehensive Cancer Center in Washington, DC, and Christopher Lieu, MD, of the University of Colorado Cancer Center in Aurora, talked through the RAS inhibitor paradigm for the treatment of patients with colorectal and pancreatic cancers.

FDA Approval Insights: Zongertinib for HER2 TKD–Mutated NSCLC: With Julia Rotow, MD; and Martin Dietrich, MD, PhD

In this episode, Julia Rotow, MD, of Dana-Farber Cancer Institute in Boston, Massachusetts, and Martin Dietrich, MD, PhD, of The US Oncology Network Cancer Care Centers of Brevard in Flroida, highlighted the significance of the accelerated FDA approval of zongertinib (Hernexeos) for the treatment of patients with HER2 TKD–mutated non–small cell lung cancer.

Community Practice Perspectives: Overcoming Barriers in Small Cell Lung Cancer Care: With Misty D. Shields, MD, PhD

In this episode, Misty D. Shields, MD, PhD, of Indiana University Health in Indianapolis, explained the ins and outs of small cell lung cancer (SCLC) management in the community oncology setting, as well as the potential clinical implications of emerging research and therapies in this area.

Variability and Innovation in Small Cell Lung Cancer Care: With Ticiana Leal, MD

In this episode, Ticiana Leal, MD, of Winship Cancer Institute, explained the wide array of SCLC management strategies used by patients in the community oncology setting, as well as the need for predictive biomarkers to guide treatment selection in this disease.

HIF-2 Targeting Is Set to Transform Kidney Cancer Management: With Chandler Park, MD; and Katy Beckermann, MD

In this episode of Oncology Unplugged, host Chandler Park, MD, of Norton Cancer Institute in Louisville, Kentucky, welcomed guest Katy Beckermann, MD, of Tennessee Oncology, to discuss the evolving role of HIF-2 targeting in the kidney cancer treatment paradigm, contextualizing their insights on the heels of ASCO GU 2026.

Watch the video podcast for more insights!

The Price of Survival: Addressing Financial Toxicity in Gynecologic Oncology With Ursula A. Matulonis, MD; and Katharine M. Esselen, MD, MBA

In this episode of From Discovery to Delivery: Charting Progress in Gynecologic Oncology, host Ursula A. Matulonis, MD, of Dana-Farber Cancer Institute, welcomed Katharine M. Esselen, MD, MBA, of Beth Israel Deaconess Medical Center in Boston, to discuss the effects of financial toxicity in gynecologic oncology.

FDA Approval Insights: Rucaparib for BRCA Mutation–Associated mCRPC: With David Morris, MD, FACS; and Alan H. Bryce, MD

In this episode, David Morris, MD, FACS, of Urology Associates, PC, in Nashville, and Alan H. Bryce, MD, of City of Hope Cancer Center Phoenix in Arizona, highlighted the significance of the full FDA approval of rucaparib (Rubraca) for the treatment of patients with BRCA mutation–associated metastatic castration-resistant prostate cancer.